David R. Epstein Sells 990 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) Director David R. Epstein sold 990 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $46.83, for a total value of $46,361.70. Following the transaction, the director now owns 26,284 shares of the company's stock, valued at approximately $1,230,879.72. The trade was a 3.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tempus AI Trading Up 6.9 %

Shares of Tempus AI stock traded up $3.31 during trading on Friday, hitting $51.35. The stock had a trading volume of 9,890,627 shares, compared to its average volume of 5,060,523. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The business has a fifty day moving average of $56.35 and a two-hundred day moving average of $51.40. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $91.45.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently modified their holdings of the stock. Operose Advisors LLC purchased a new stake in shares of Tempus AI during the fourth quarter valued at $25,000. First Horizon Advisors Inc. purchased a new stake in shares of Tempus AI during the third quarter valued at $30,000. Farther Finance Advisors LLC purchased a new stake in shares of Tempus AI during the fourth quarter valued at $34,000. Prestige Wealth Management Group LLC lifted its holdings in shares of Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after purchasing an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC purchased a new stake in shares of Tempus AI during the fourth quarter valued at $49,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Bank of America increased their price target on Tempus AI from $54.00 to $60.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. Guggenheim reissued a "buy" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Wolfe Research cut Tempus AI from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Needham & Company LLC increased their price target on Tempus AI from $56.00 to $70.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Finally, TD Cowen reissued a "buy" rating and issued a $74.00 price target (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $61.18.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.